Dexamethasone
- TRADE NAMES: Cortastat; Decadron (Merck); Dexone (Solvay); Hexadrol; Ozurdex (Allergan)
- INDICATIONS: Antiemetic, arthralgias, dermatoses, diagnostic aid, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), non-infectious uveitis affecting the posterior segment of the eye
- CLASS: Antiemetic, Corticosteroid / Glucocorticoid, Corticosteroid, systemic, Corticosteroid, topical, Covid-19 putative drug
- HALF-LIFE: N/A
Albendazole, Aminoglutethimide, Amprenavir, Aprepitant, Aspirin, Bexarotene, Boceprevir, Carbamazepine, Caspofungin, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Cyclophosphamide, Dasatinib, Delavirdine, Diuretics, Ephedrine, Imatinib, Itraconazole, Ixabepilone, Lapatinib, Lenalidomide, Live vaccines, Lopinavir, Methotrexate, Midazolam, Phenobarbital, Phenytoin, Praziquantel, Primidone, Rifampin, Rilpivirine, Romidepsin, Simeprevir, Sorafenib, Sunitinib, Telaprevir, Temsirolimus, Ticagrelor, Vandetanib, Warfarin
PREGNANCY CATEGORY: C
See adverse reactions attributed to class:
Acneiform eruption / acneiform dermatitis / acneiform rash
(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]
(2016): Yanaranop M+, Asia Pac J Clin Oncol 12(3), 2892–11%
(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2006): Vardy J+, Br J Cancer 94(7), 101115%
(1997): Borgna-Pignatti+, J Pediatr 130(1), 13-6
Acute generalized exanthematous pustulosis (AGEP)
(2009): Momin SB+, Cutis 83(6), 291 (with meloxicam and thalidomide)
(1995): Demitsu T+, Dermatology 193, 56
Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)
(2012): Lonial S+, J Clin Oncol 30(16), 1953 (1 case) (with elotuzumab and lenalidomide)
(2009): Shirahata A+, Gan To Kagaku Ryoho 36 (8), 1383
(1997): Figueredo E+, Allergy 52(8), 877
Bruise / bruising / contusion / ecchymosis (ecchymoses)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Dermatitis
(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)
(2002): Nucera E+, Dermatology 204(3), 248
(2000): Chew AL+, Cutis 65, 307
(1994): Whitmore SE, Br J Dermatol 131, 296 (generalized)
(1989): Rivara G+, Contact Dermatitis 21(2), 83-9 [REVIEW]
Edema / fluid retention (see also peripheral edema)
(2017): Palladini G+, Blood 129(15), 2120 (with pomalidomide)
(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
(1998): Berinstein TH+, Ear Nose Throat J 77(1), 40-3
Embolia cutis medicamentosa (Nicolau syndrome)
(1997): Kohler LD+, Int J Dermatol 36(3), 197 (with diclofenac)
Erythema multiforme
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
Exanthems
(2015): Gupta N+, J Hematol Oncol 8, 103 (7 cases) (with lenalidomide and ixazomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2010): Subedi BH+, Wilderness Environ Med 21(4), 345
(1987): Maucher OM+, Hautarzt (German) 38, 577
Exfoliative dermatitis
(2015): Gupta N+, J Hematol Oncol 8, 103 (2 cases) (with lenalidomide and ixazomib)
Flushing / rubefaction
(2015): El Abd O+, Pain Physician 18(3), 277
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2002): Toth GG+, J Eur Acad Dermatol Venereol 16(6), 607
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
(1999): Toth GG+, Ther Drug Monit 21(5), 532
Herpes zoster
(2016): Shimazaki C+, Int J Hematol 103(1), 79 (grade 3 / 1 case) (with bortezomib and melphalan)
(2015): Tsukada N+, Rinsho Ketsueki 56(8), 1069 (grade 3 / 2 cases) (reactivation / with bortezomib and cyclophosphamide)
Hyperhidrosis
(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)
(2012): Lonial S+, J Clin Oncol 30(16), 195311% (with elotuzumab and lenalidomide)
Hypersensitivity
(2016): Yamamoto T+, Eur J Gynaecol Oncol 37(6), 83352–54% (with paclitaxel and aprepitant)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 60674% (with oxaliplatin)
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
(1993): Chan AT, BMJ 306, 109
(1993): Williams WR, BMJ 306(6877), 585
(1986): Baldinger J+, Ann Ophthalmol eact(3), 95-6 (with polymyxin B/neomycin)
Necrotizing fasciitis
(2014): Mondello P+, Springerplus 3, 123 [REVIEW] (with ibandronate and lenalidomide)
Peripheral edema (see also edema)
(2020): Palladini G+, Blood Apr, Epub ahead of print50% (with daratumumab, cyclophosphamide and bortezomib)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2016): Mateos MV+, Br J Haematol 175(3), 44825% (grade 3+) (with elotuzumab and thalidomide)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Usmani SZ+, Blood Cancer J 5, e33483% (with bortezomib, elotuzumab and lenalidomide)
(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)
(2002): Hempen C+, Support Care Cancer 10(4), 322
(1991): Weissman DE+, J Neurooncol 11(3), 235
Pigmentation
(2015): Gupta N+, J Hematol Oncol 8, 103 (6 cases) (with lenalidomide and ixazomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Pruritus (itching)
(2015): Gupta N+, J Hematol Oncol 8, 103 (10 cases) (with lenalidomide and ixazomib)
(2004): Crandell JT, Can J Anaesth 51(4), 398
(2004): Kuczkowski KM, Anaesthesia 59(3), 308
(2003): Perron G+, Can J Anaesth 50(7), 749
(2001): Dong Y+, Chin Med J (Engl) 114(7), 764 (with methotrexate)
(1999): Alexiou C+, Laryngorhinootologie 78(10), 573
(1988): Taleb N+, Eur J Cancer Clin Oncol 24(3), 495
Pruritus ani et vulvae
(2015): El Abd O+, Pain Physician 18(3), 2774%
(2012): Gu CY+, Pharmazie 67(12), 1015
Rash
(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (5 cases) (with lenalidomide)
(2016): Mateos MV+, Lancet Oncol 175(3), 4483% (grade 3) (with lenalidomide)
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2014): Wang YS+, Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese) 45(3), 52967% (with bortezomib and thalidomide)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195311% (with elotuzumab and lenalidomide)
(2010): Subedi BH+, Wilderness Environ Med 21(4), 345
(2003): Jain R+, J Dermatol 30(10), 713 (3 cases) (with cyclophosphamide)
Septic–toxic shock
(2017): Kwon J+, Cancer Med 6(1), 100 (fatal / 2 cases)
(with cyclophosphamide and thalidomide)
Skin toxicity / toxicity
(2016): Pan Z+, Int J Cancer 139(8), 186420% (grade 3 or 4) (with methotrexate and radiotherapy)
(2014): Rasche L+, Ann Hematol 93(7), 1207 (with carmustine, cytarabine, etoposide and melphalan)
(2012): Khan ML+, Br J Haematol 156(3), 326 (with bortezomib, cyclophosphamide and lenalidomide)
(2011): Kumar SK+, Am J Hematol 86(8), 640 (with cyclophosphamide and lenalidomide)
(2003): Belgaumi AF+, Cancer 97(11), 2898 (with daunomycin)
Stevens-Johnson syndrome
(2012): Siniscalchi A+, Support Care Cancer 20(7), 1585 (with lenalidomide)
Striae
(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6
(1992): Pang S+, J Clin Endocrinol 75(1), 249
(1985): Job JC+, Arch Fr Pediatr 42(9), 765
(1983): Guest G+, Arch Fr Pediatr 40(6), 453
Toxic epidermal necrolysis (Lyell's syndrome)
(2003): Hall VC+, J Am Acad Dermatol 48(4), 548 (with thalidomide)
Urticaria / hives
(1995): Valdivieso R+, J Investig Allergol Clin Immunol 5(3), 171 (2 cases) (with paramethasone)
Xerosis
(2015): Gupta N+, J Hematol Oncol 8, 103 (4 cases) (with lenalidomide and ixazomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Abnormal hair growth
(2015): Gupta N+, J Hematol Oncol 8, 103 (1 case) (with lenalidomide and ixazomib)
Burning Mouth Syndrome / glossodynia / glossalgia / glossopyrosis (also includes stomatodynia / oral dysesthesia / stomatopyrosis)
(2017): Zadik Y+, Expert Opin Pharmacother 18(3), 235
Oral candidiasis
(2001): Hardy JR+, Palliat Med 15(1), 3-8
(1983): Hanks GW+, Postgrad Med J 59(697), 702
Bradycardia / sinus bradycardia
(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print46%
(2015): Stroeder J+, Can Pharm J (Ott) 148(5), 235 [REVIEW]
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Dossabhoy NR+, J La State Med Soc 165(5), 283
(2013): Marinov M+, Br J Anaesth 111(6), 1025
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
(2005): Palladini G+, Blood 105(7), 294926% (with thalidomide)
(1988): Ohlsson A+, Lancet 2(8619), 1074
(1988): Puntis JW+, Lancet 2(8624), 1372
Cardiac failure
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Cardiotoxicity
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)
(2014): Atalay F+, J Med Case Rep 8, 252 (with cyclophosphamide, doxorubicin, rituximab and vincristine)
Hypertension
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print2% (grade 3+) (with lenalidomide)
(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print52%
(2016): Berenson JR+, Blood 127(26), 33607% (grade 3+) (with carfilzomib)
(2016): Dimopoulos MA+, Lancet Oncol 17(1), 273–9% (grade 3+) (with bortezomib or carfilzomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2006): Wallenborn J+, BMJ 333(7563), 324 (with metoclopramide)
(2003): Halliday HL+, Cochrane Database Syst (1), CD001146 [REVIEW]
(2003): Jain R+, J Dermatol 30(10), 7133% (with cyclophosphamide)
(2001): Halliday HL+, Pediatrics 107(2), 232
(1999): Fuchs M+, HNO 47(7), 647
(1998): Hari P+, Indian J Pediatr 65(4), 557 [REVIEW]
(1996): Smets K+, Eur J Pediatr 155(7), 573
(1995): Caulier MT+, Br J Haematol 91(2), 477
(1992): Greenough A+, Eur J Pediatr 151(2), 134
(1992): Pang S+, J Clin Endocrinol Metab 75(1), 249
(1990): Ferrara TB+, J Perinatol 10(2), 137
(1989): Merz U+, Klin Padiatr 201(1), 11-5
Myocardial toxicity
(2005): Balys R+, Int J Pediatr Otorhinolaryngol 69(2), 271
(2003): Halliday HL+, Cochrane Database Syst Rev (1), CD001146 [REVIEW]
(2003): Lilien LD+, Pediatr Cardiol 24(3), 280
(2000): Takagi S+, Jpn Circ J 64(10), 785
(1998): Fritz KI+, J Perinatol 18(1), 38-4 [REVIEW]
(1998): Kothari SN+, Surgery 123(1), 102
(1997): Boeuf B+, Arch Pediatr 4(2), 152 [REVIEW]
(1997): Miranda-Mallea J+, Eur J Pediatr 156(5), 394
(1996): Villa Alcazar M+, An Esp Pediatr 44(4), 393 [REVIEW]
(1995): Haney I+, Am J Perinatol 12(4), 271
(1995): Pokela ML, Duodecim 111(14), 1310
Pericardial effusion
(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)
Tachycardia
(2006): Wallenborn J+, BMJ 333(7563), 324 (with metoclopramide)
(2005): Balys R+, Int J Pediatr 69(2), 271
Thromboembolism
(2017): Maharaj S+, Expert Rev Anticancer Ther 17(7), 585 [REVIEW] (arterial / with lenalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
Venous thromboembolism
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2014): Baz RC+, Am J Hematol 89(1), 629% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2013): Fouquet G+, Cancer 119(20), 368020% (with lenalidomide)
(2013): Mateos MV+, N Engl J Med 369(5), 4382–3% (grade 1–2) (with lenalidomide)
(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)
Anorexia
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2014): Hamada S+, Support Care Cancer 22(8), 21613% (with aprepitant and palonosetron)
Anxiety
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Catatonia
(2016): Vanstechelman S+, Acta Clin Belg 71(6), 438
(2011): Dada MU+, Afr J Psychiatry (Johannesbg) 14(4), 316
Dysgeusia (taste perversion)
(2005): Herr BD+, Otolaryngol Head Neck Surg 132(4), 527
(2003): Jain R+, J Dermatol 30(10), 71313% (with cyclophosphamide)
(1993): Pasricha JS+, Int J Dermatol 32(10), 753
Fever (pyrexia)
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2013): Wang M+, Blood 122(18), 312244% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 11612% (with thalidomide)
(1997): McIntyre PB+, JAMA 278(11), 925
(1994): Pichard E+, Isr J Med Sci 30(5-6), 408
Headache <5%
(2015): El Abd O+, Pain Physician 18(3), 277
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2012): Lonial S+, J Clin Oncol 30(16), 195321% (with elotuzumab and lenalidomide)
(2003): Jain R+, J Dermatol 30(10), 71316% (with cyclophosphamide)
(2001): Dong Y+, Chin Med J (Engl) 114(7), 764 (with methotrexate)
(1998): Goedhals L+, Ann Oncol 9(6), 661 (with granisetron)
(1998): Martoni A+, Anticancer Res 18(4B), 2799 (with granisetron)
(1993): Pasricha JS+, Int J Dermatol 32(10), 753
Insomnia
(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331
(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]
(2015): El Abd O+, Pain Physician 18(3), 277
(2015): Gupta N+, J Hematol Oncol 8, 10312% (with lenalidomide and ixazomib)
(2015): Ocio EM+, Haematologica 100(7), e289 (with panobinostat)
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2014): Roila F+, J Clin Oncol 32(2), 1013%
(2013): Wang M+, Blood 122(18), 312235% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)
Irritability
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Leukoencephalopathy / posterior reversible encephalopathy syndrome (PRES))
(2009): Nguyen MT+, J Clin Neurosci 16(12), 1688 (with Cisplatin)
(2006): Pandey R+, Leuk Lymphoma 47(7), 1431 (with thalidomide)
Neuropsychiatric / neuropsychological adverse effect
(2021): Oyake M+, Pediatr Int Feb, Online ahead of print (1 case / female)
(2020): Phillips NS+, Pediatr Blood Cancer 67(3), e27968
(2016): Warris LT+, J Clin Oncol 34(19), 2287-93
(2014): Hitzert MM+, Early Hum Dev 90(5), 253-8
(2014): Warris LT+, Pediatr Blood Cancer 61(7), 1313-8 [REVIEW]
(2013): Edelmann MN+, Pediatr Blood Cancer 60(11), 1778-84
Neurotoxicity
(2017): Berdeja JG+, Br J Haematol 177(2), 254 (with bendamustine and bortezomib)
(2016): Levinsen M+, J Pediatr Hematol Oncol 38(8), 60222% (with cytarabine)
(2016): Pan Z+, Int J Cancer 139(8), 1864 (with methotrexate and radiotherapy)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)
(2014): Leiba M+, Br J Haematol 166 (5), 702 [REVIEW]11% (grade 3 or 4) (with bortezomib and thalidomide)
(2014): Richardson PG+, Blood 123(10), 146153% (with bortezomib and lenalidomide)
(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 116124% (with thalidomide)
(2010): Richardson PG+, Blood 116(5), 67980% (with lenalidomide and bortezomib)
Paresthesias
(2015): El Abd O+, Pain Physician 18(3), 27712%
(1986): Rasche H+, Dtsch Med Wochenschr 111(37), 1406
Peripheral neuropathy
(2020): Terpos E+, Ann Hematol Apr, Epub ahead of print35% (3% grade 3–4) (with ixazomib and lenalidomide)
(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print15% (with bortezomib (SC administered) and panobinostat)
(2018): Iida S+, Cancer Sci Feb, Epub ahead of print9–23% (grade 3 or 4) (with bortezomib or thalidomide)
(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print3% (grade 3+) (with lenalidomide)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print24% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2018): Terpos E+, Eur J Haematol 100(1), 1023–37% (with bortezomib)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2017): Zhang YP+, Eur J Haematol 99(6), 48960% (with bortezomib)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]61% (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Shimazaki C+, Int J Hematol 103(1), 7916% (with bortezomib and melphalan)
(2015): Gupta N+, J Hematol Oncol 8, 10326% (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33483% (with bortezomib, elotuzumab and lenalidomide)
(2014): Bringhen S+, Blood 124(1), 639% (grade 1 or 2) (with carfilzomib and cyclophosphamide)
(2014): Cook G+, Lancet Oncol 15(8), 87412% (with bortezomib and doxorubicin)
(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 119515% (grade 3 or 4) (with bortezomib)
(2014): Wang YS+, Sichuan Da Xue Xue Bao Yi Xue Ban (Chinese) 45(3), 5297% (grade 3) (with bortezomib and thalidomide)
(2014): Zhang Y+, Pathol Oncol Res 20(4), 9878–33% (with bortezomib and doxorubicin)
(2013): Dimopoulos MA+, Blood 122(19), 327646% (with bortezomib and rituxuimab)
(2013): Richardson PG+, Blood 122(14), 2331 (grade 3 / 1 case) (with bortezomib and panobinostat)
(2013): Voorhees PM+, Blood 121(5), 858 (with bortezomib and lenalidomide)
(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167525% (with bortezomib, doxorubicin and lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180123% (low-dose / with carfilzomib and lenalidomide)
(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)
Psychosis
(2021): Alsalamah A+, SAGE Open Med Case Rep Oct, eCollection (1 case / male)
(2021): Kazi SE+, Cureus 13(9), e18093 (1 case / female)
(2019): Fischer M+, WMJ 118(2), 91 [REVIEW] (1 case)
(2019): Janes M+, Proc (Bayl Univ Med Cent) 32(4), 614-615 (1 case / male)
(2011): Dada MU+, Afr J Psychiatry (Johannesbg) 14(4), 316
Somnolence (drowsiness)
(2017): Nakashima K+, Jpn J Clin Oncol 47(9), 84013% (with aprepitant, olanzapine and palonosetron)
(2011): Hus M+, Ann Hematol 90(10), 116110% (with thalidomide)
Vertigo / dizziness
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]
(2011): Hus M+, Ann Hematol 90(10), 116110% (with thalidomide)
Alanine aminotransferase (ALT) increased
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Wang M+, Blood 122(18), 312214% (with carfilzomib and lenalidomide)
Alkaline phosphatase (ALP) increased
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
Aspartate aminotransferase (AST) increased
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (3 cases) (with oxaliplatin)
Cushing's syndrome
(2017): Franke V+, BMJ Case Rep Apr, Epub (in a herbal preparation)
(2012): Dutta D+, J Clin Res Pediatr Endocrinol 4(3), 157 (from intranasal)
Dehydration
(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print26% (grade 3 or 4) (with bortzomib and panobinostat)
(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)
(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)
Hyperglycemia (includes glucose increased)
(2021): Toroghi N+, Pharmacol Rep Nov, Online ahead of print30%–48% (with concomitant medication)
(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print63%
(2017): Badros A+, Blood 130(10), 118925% (grade 3 or 4) (with pembrolizumab and pomalidomide)
(2016): Hatano Y+, BMJ Support Palliat Care 6(3), 331
(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]
(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180123% (low-dose / with carfilzomib and lenalidomide)
(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)
(2012): Zhang YP+, Biomed Environ Sci 25(3), 311 (after intravitreal surgery)
Hypocalcemia
(2014): Noriega Aldave AP+, J Med Case Rep 8, 353 (with bortezomib, lenalidomide and zoledronate)
Hypokalemia
(2015): Gupta N+, J Hematol Oncol 8, 1037% (grade 3+) (with lenalidomide and ixazomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Richardson PG+, Blood 122(14), 233122% (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312225% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195329% (with elotuzumab and lenalidomide)
Hypophosphatemia
(2013): Richardson PG+, Blood 122(14), 23316% (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312239% (with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180125% (low-dose / with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47223% (with lenalidomide and perifosine)
Serum creatinine increased
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 18263% (grade 3 or 4) (with pomalidomide)
Weight loss
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
Abdominal distension
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Richardson PG+, Blood 122(14), 233120% (with bortezomib and panobinostat)
Abdominal pain
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2014): Hamada S+, Support Care Cancer 22(8), 21613% (with aprepitant and palonosetron)
(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]
(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)
(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6
Constipation
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2017): Moreau P+, Blood 130(22), 239241% (with bortezomib and venetoclax)
(2016): Kobayashi K+, J Clin Oncol 34(26_suppl), 226 (mild) (with aprepitant and palonosetron)
(2016): Yang CK+, Biomed J 39(1), 6043% (with aprepitant and palonosetron)
(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)
(2014): Takeshima N+, Support Care Cancer 22(11), 2891 (3 cases) (with aprepitant and palonosetron)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Wang M+, Blood 122(18), 312227% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195339% (with elotuzumab and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 116114% (with thalidomide)
Diarrhea
(2020): Palladini G+, Blood Apr, Epub ahead of print68% (with daratumumab, cyclophosphamide and bortezomib)
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print18% (grade 3 or 4) (with bortezomib and panobinostat)
(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2017): Moreau P+, Blood 130(22), 239246% (with bortezomib and venetoclax)
(2016): Mu S+, Eur J Clin Pharmacol 72(2), 153 (with bortezomib and panobinostat)
(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]25% (grade 3 or 4) (with bortezomib and panobinostat)
(2015): Gupta N+, J Hematol Oncol 8, 10340% (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Richardson PG+, Lancet Haematol 2(12), e51666% (with elotuzumab and lenalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (2 cases) (with oxaliplatin)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 11958% (grade 3 or 4) (with bortezomib)
(2014): Siegel DS+, Blood Cancer J 4, e18255% (with lenalidomide and vorinostat)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Richardson PG+, Blood 122(14), 233171% (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312258% (with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47245% (with lenalidomide and perifosine)
(2012): Lonial S+, J Clin Oncol 30(16), 195350% (with elotuzumab and lenalidomide)
Dyspepsia / functional dyspepsia / gastroparesis
(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print24%
(2016): Navari RM, Expert Opin Drug Saf 15(3), 343 [REVIEW]
(2014): Roila F+, J Clin Oncol 32(2), 1018%
Gastroesophageal reflux
(2018): Sing EPC+, J Pediatr Hematol Oncol Apr, Epub ahead of print24%
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Gastrointestinal disorder / discomfort
(2015): Korde N+, JAMA Oncol 1(6), 74692% (with carfilzomib and lenalidomide)
(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)
(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79014% (with cisplatin, etoposide and ifosfamide)
(2015): Ding H+, Int J Hematol 102(2), 181 (with etoposide, methotrexate and pegaspargase)
(2014): Zhang Y+, Pathol Oncol Res 20(4), 98713–43% (with bortezomib and doxorubicin)
(2012): Miller RJ+, Can J Neurol Sci 39(4), 547 (with temozolomide)
Nausea
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2017): Moreau P+, Blood 130(22), 239238% (with bortezomib and venetoclax)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79066% (with cisplatin, etoposide and ifosfamide)
(2015): Gupta N+, J Hematol Oncol 8, 10316% (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (2 cases) (with oxaliplatin)
(2013): Gurung V+, Cochrane Database Syst Rev 6, CD000493 [REVIEW]
(2013): Richardson PG+, Blood 122(14), 233160% (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312235% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195343% (with elotuzumab and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
Pancreatitis / acute pancreatitis
(2014): Keino D+, Rinsho Ketsueki (Japanese) 55(3), 327 (with bortezomib, doxorubicin and vincristine)
(2010): Vinklerova I+, Dig Dis Sci 55(10), 2977 (1 case)
Vomiting
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2016): Aljebab F+, Arch Dis Child 101(4), 365 [REVIEW]
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79066% (with cisplatin, etoposide and ifosfamide)
(2015): Gupta N+, J Hematol Oncol 8, 10321% (with lenalidomide and ixazomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)
(2011): Hus M+, Ann Hematol 90(10), 11612% (with thalidomide)
Urinary tract infection
(2014): Richardson PG+, Blood 123(12), 18269% (grade 3 or 4) (with pomalidomide)
Anemia
(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)
(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print28% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43325% (grade 3+) (with carfilzomib and cyclophosphamide)
(2017): Hou J+, J Hematol Oncol 10(1), 1372–26% (grade 3 or 4) (with lenalidomide)
(2017): Lu J+, Br J Haematol 176(5), 74319% (grade 3 or 4) (with lenalidomide)
(2017): Moreau P+, Eur J Haematol 99(3), 19932% (grade 3 or 4) (with pomalidomide)
(2017): Moreau P+, Blood 130(22), 239215% (grade 3 or 4) (with bortezomib and venetoclax)
(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)
(2016): Dimopoulos MA+, Lancet Oncol 17(1), 2710–14% (grade 3+) (with bortezomib or carfilzomib)
(2016): Du X+, BMC Cancer 16(1), 4611% (grade 3 or 4) (with lenalidomide)
(2016): Palumbo A+, N Engl J Med 375(8), 75416% (grade 3 or 4) (with bortezomib)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79068% (with dexamethasone, etoposide and ifosfamide)
(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]20% (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Suzuki K+, Cancer Sci 107(5), 65319% (grade 3 or 4) (with lenalidomide)
(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278715% (grade 3 or 4) (with cisplatin and gemcitabine)
(2015): Ding H+, Int J Hematol 102(2), 18123% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)
(2015): Gupta N+, J Hematol Oncol 8, 1037% (grade 3+) (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortzomib and palbociclib)
(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)
(2014): Baz RC+, Am J Hematol 89(1), 6216% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2014): Bringhen S+, Blood 124(1), 6311% (grade 3+) (with carfilzomib and cyclophosphamide)
(2014): Hopfinger G+, Ann Hematol 93(3), 4598% (grade 3+) (with lenalidomide and vorinostat)
(2014): Richardson PG+, Blood 123(12), 182622% (grade 3 or 4) (with pomalidomide)
(2014): Siegel DS+, Blood Cancer J 4, e18258% (with lenalidomide and vorinostat)
(2013): Fouquet G+, Cancer 119(20), 36806% (grade 3–4) (with lenalidomide)
(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 1 case) (with docetaxel and estramustine)
(2013): Lamm W+, J Cancer Res Clin Oncol 139(10), 177117% (grade 2+) (with cytarabine, oxaliplatin and rituximab)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 105537% (grade 3 or 4) (high-dose)
(2013): Richardson PG+, Blood 122(14), 233147% (with bortezomib and panobinostat)
(2013): San Miguel J+, Lancet Oncol 14(11), 105537% (grade 3 or 4) (high-dose)
(2013): Wang M+, Blood 122(18), 312233% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167530% (with bortezomib, doxorubicin and lenalidomide)
(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180121% (low-dose / with carfilzomib and lenalidomide)
(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195346% (with elotuzumab and lenalidomide)
Coagulopathy (includes disseminated intravascular coagulation / DIC)
(2016): Zhang L+, Oncotarget 7(34), 5572158% (with cisplatin, gemcitabine and pegaspargase)
Eosinophilia
(2014): Sekiguchi Y+, Indian J Hematol Blood Transfus 30(Suppl 1), 264 [REVIEW] (with lenalidomide)
Febrile neutropenia
(2019): Tanaka K+, Acta Haematol 141(2), 111 (with cyclophosphamide and bortezomib)4 cases (with cyclophosphamide and bortezomib)
(2017): Sangha R+, J Drug Assess 6(1), 10 (2 cases) (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)
(2014): Baz RC+, Am J Hematol 89(1), 629% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 18263% (grade 3 or 4) (with pomalidomide)
(2012): Chanan-Khan AA+, Int J Hematol 96(2), 254 (with lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 19537% (with elotuzumab and lenalidomide)
(2012): Zaja F+, Haematologica 97(3), 41612% (with lenalidomide)
(2011): Park BB+, Invest New Drugs 29(1), 1542% (with gemcitabine, ifosfamide and oxaliplatin)
Granulocytopenia
(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)
Hematological adverse effect
(2019): Tanaka K+, Acta Haematol 141(2), 1111 case (grade 4 ) (with cyclophosphamide and bortezomib)
Hemoglobin decreased
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2013): Wang M+, Blood 122(18), 31228% (with carfilzomib and lenalidomide)
Hemorrhage
(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)
Hemotoxicity
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2017): Badros A+, Blood 130(10), 118940% (grade 3 or 4) (with pembrolizumab and pomalidomide)
(2017): Rosenthal A+, Am J Hematol 92(5), 467 (with cyclophosphamide, lenalidomide and rituximab)
(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (4 cases) (with lenalidomide)
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2015): Rodon P+, Haematologica 100(2), e56 (with bendamustine and bortezomib)
(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)
(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)
Leukocytopenia (leukopenia)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print33% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43313% (grade 3+) (with carfilzomib and cyclophosphamide)
(2017): Einsele H+, Br J Haematol 179(4), 58631% (grade 3+) (with bortezomib and cyclophosphamide)
(2016): Zhang L+, Oncotarget 7(34), 5572158% (grade 3 or 4) (with cisplatin, gemcitabine and pegaspargase)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)
(2014): Hopfinger G+, Ann Hematol 93(3), 45915% (grade 3+) (with lenalidomide and vorinostat)
(2014): Richardson PG+, Blood 123(12), 182610% (grade 3 or 4) (with pomalidomide)
(2013): Wang M+, Blood 122(18), 312221% (with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47213% (with lenalidomide and perifosine)
(2012): Kim SJ+, Invest New Drugs 30(1), 368 (with alemtuzumab, cisplatin and cytarabine)
(2012): Zaja F+, Haematologica 97(3), 41625% (with dexamethasone)
Leukocytosis (elevated white blood cell (WBC) count)
(2021): Toroghi N+, Pharmacol Rep Nov, Online ahead of print38%–48% (with concomitant medication)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Lymphopenia (lymphocytopenia) / lymphocytes decreased
(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)
(2015): Korde N+, JAMA Oncol 1(6), 746100% (with carfilzomib and lenalidomide)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Richardson PG+, Lancet Haematol 2(12), e51621% (grade 3 or 4) (with elotuzumab and lenalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33466% (with bortezomib, elotuzumab and lenalidomide)
(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)
(2014): Richardson PG+, Blood 123(10), 146111% (grade 3 or 4) (with bortezomib and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 18267% (grade 3 or 4) (with pomalidomide)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 119540% (grade 3 or 4) (with bortezomib)
(2013): Wang M+, Blood 122(18), 312252% (with carfilzomib and lenalidomide)
(2010): Richardson PG+, Blood 116(5), 67914% (with lenalidomide and bortezomib)
Myelosuppression / bone marrow suppression / myelotoxicity
(2016): Pan Z+, Int J Cancer 139(8), 1864 (with methotrexate and radiotherapy)
(2014): Li M+, Leuk Lymphoma 55(7), 1578 (with bleomysin, cyclophosphamide, cytarabine and vindesine)
(2013): Gras J, Drugs Today (Barc) 49(9), 555 [REVIEW] (with pomalidomide)
(2013): Leleu X+, Blood 121(11), 1968 (with pomalidomide)
(2011): Lacy MQ+, Blood 118(11), 2970 (low dose / with pomalidomide)
Neutropenia (neutrophils decreased)
(2018): Cohen A+, Br J Haematol 180(1), 6059% (grade 3+) (with doxorubicin and pomalidomide)
(2018): Dimopoulos MA+, Eur J Cancer 106, 8931% (with ixazomib and cyclophosphamide)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print38% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43319% (grade 3+) (with carfilzomib and cyclophosphamide)
(2017): Hou J+, J Hematol Oncol 10(1), 1372–19% (grade 3 or 4) (with lenalidomide)
(2017): Itai S+, J Pharm Health Care Sci 3, 3
(2017): Lu J+, Br J Haematol 176(5), 74325% (grade 3 or 4) (with lenalidomide)
(2017): Moreau P+, Eur J Haematol 99(3), 19956% (grade 3 or 4) (with pomalidomide)
(2017): Paludo J+, Br J Haematol 179(1), 9820% (grade 3+) (with cyclophosphamide and rituximab)
(2017): Richardson PG+, Leukemia 31(12), 269544% (grade 3 or 4) (with bortezomib and pomalidomide)
(2017): Sangha R+, J Drug Assess 6(1), 1069% (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)
(2017): Tanaka N+, Jpn J Clin Oncol 47(3), 247 (with docetaxel)
(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)
(2016): Du X+, BMC Cancer 16(1), 4620% (grade 3 or 4) (with lenalidomide)
(2016): Mateos MV+, Lancet Oncol 17(8), 11275% (grade 3) (with lenalidomide)
(2016): Palumbo A+, N Engl J Med 375(8), 7544% (grade 3 or 4) (with bortezomib)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79085% (with cisplatin, etoposide and ifosfamide)
(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)
(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]35% (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Suzuki K+, Cancer Sci 107(5), 65323% (grade 3 or 4) (with lenalidomide)
(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278734% (grade 3 or 4) (with cisplatin and gemcitabine)
(2015): Ding H+, Int J Hematol 102(2), 18146% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)
(2015): Gupta N+, J Hematol Oncol 8, 10319% (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Richardson PG+, Lancet Haematol 2(12), e51619% (grade 3 or 4) (with elotuzumab and lenalidomide)
(2015): Tsukada N+, Rinsho Ketsueki 56(8), 1069 (grade 4 / 2 cases) (with bortezomib and cyclophosphamide)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (4 cases) (with oxaliplatin)
(2014): Baz RC+, Am J Hematol 89(1), 6249% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2014): Bringhen S+, Blood 124(1), 6320% (grade 3+) (with carfilzomib and cyclophosphamide)
(2014): Cook G+, Lancet Oncol 15(8), 87443% (with bortezomib and doxorubicin)
(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)
(2014): Hopfinger G+, Ann Hematol 93(3), 4598% (grade 3+) (with lenalidomide and vorinostat)
(2014): Richardson PG+, Blood 123(10), 146142% (with bortezomib and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 182641% (grade 3 or 4) (with pomalidomide)
(2013): Fouquet G+, Cancer 119(20), 368016% (grade 3–4) (with lenalidomide)
(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 1 case) (with docetaxel and estramustine)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 105516% (grade 3 or 4) (high-dose)
(2013): Richardson PG+, Blood 122(14), 233118% (with bortezomib and panobinostat)
(2013): San Miguel J+, Lancet Oncol 14(11), 105516% (grade 3 or 4) (high-dose)
(2013): San-Miguel JF+, J Clin Oncol 31(29), 369647–64% (grade 3 or 4) (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167535% (with bortezomib, doxorubicin and lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180117% (low-dose / with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47226% (with lenalidomide and perifosine)
(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195339% (with elotuzumab and lenalidomide)
(2012): Zaja F+, Haematologica 97(3), 41653% (with lenalidomide)
(2011): Park BB+, Invest New Drugs 29(1), 154 (with gemcitabine, ifosfamide and oxaliplatin)
(2010): Richardson PG+, Blood 116(5), 6799% (with lenalidomide and bortezomib)
Prothrombin time (INR) increased
(2016): Zhang L+, Oncotarget 7(23), 5572150% (with cisplatin, gemcitabine and pegaspargase)
Sepsis
(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)
(2013): Richardson PG+, Blood 122(14), 23316–9% (with bortezomib and panobinostat)
(2012): Teoh G+, Clin Lymphoma Myeloma Leuk 12(2), 118 (with thalidomide and zoledronic acid)
Thrombocytopenia
(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print47% (grade 3 or 4) (with bortezomib and panobinostat)
(2018): Iida S+, Cancer Sci Feb, Epub ahead of print55% (grade 3 or 4) (with bortezomib)
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print15% (grade 3+) (with lenalidomide)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print29% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2018): Terpos E+, Eur J Haematol 100(1), 109–22% (grade 3+) (with bortezomib)
(2017): Einsele H+, Br J Haematol 179(4), 5867% (grade 3+) (with bortezomib and cyclophosphamide)
(2017): Hou J+, J Hematol Oncol 10(1), 1375–14% (grade 3 or 4) (with lenalidomide)
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2017): Moreau P+, Eur J Haematol 99(3), 19926% (grade 3 or 4) (with pomalidomide)
(2017): Moreau P+, Blood 130(22), 239229% (grade 3 or 4) (with bortezomib and venetoclax)
(2017): Paludo J+, Br J Haematol 179(1), 987% (grade 3+) (with cyclophosphamide and rituximab)
(2017): Richardson PG+, Leukemia 31(12), 269526% (grade 3 or 4) (with bortezomib and pomalidomide)
(2017): Sangha R+, J Drug Assess 6(1), 1085% (with cisplatin, gemcitabine, inotuzumab ozogamicin and rituximab)
(2017): Zhang YP+, Eur J Haematol 99(6), 489 (with bortezomib)
(2016): Dimopoulos MA+, Lancet Oncol 17(1), 278–9% (grade 3+) (with bortezomib or carfilzomib)
(2016): Mu S+, Eur J Clin Pharmacol 72(2), 153 (with bortezomib and panobinostat)
(2016): Palumbo A+, N Engl J Med 375(8), 75433% (grade 3 or 4) (with bortezomib)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 79041% (with cisplatin, etoposide and ifosfamide)
(2016): Plesner T+, Blood 128(14), 1821>5% (grade 3 or 4) (with daratumumab and lenalidomide)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]67% (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Shah JJ+, Blood Cancer J 6, e396 (grade 4) (with bortezomib, lenalidomide and siltuximab)
(2016): Shimazaki C+, Int J Hematol 103(1), 7947% (with bortezomib and melphalan)
(2016): Wang JJ+, Medicine (Baltimore) 95(6), e278720% (grade 3 or 4) (with cisplatin and gemcitabine)
(2016): Zhang L+, Oncotarget 7(34), 5572146% (grade 3 or 4) (with cisplatin, gemcitabine and pegaspargase)
(2015): Ding H+, Int J Hematol 102(2), 18131% (grade 3 or 4) (with etoposide, methotrexate and pegaspargase)
(2015): Gupta N+, J Hematol Oncol 8, 10319% (with lenalidomide and ixazomib)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Usmani SZ+, Blood Cancer J 5, e33450% (with bortezomib, elotuzumab and lenalidomide)
(2014): Baz RC+, Am J Hematol 89(1), 627% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2014): Cook G+, Lancet Oncol 15(8), 87451% (with bortezomib and doxorubicin)
(2014): Craig M+, Br J Haematol 166(6), 920 (with bortezomib, cyclophosphamide, prednisone and rituximab)
(2014): Hopfinger G+, Ann Hematol 93(3), 45923% (grade 3+) (with lenalidomide and vorinostat)
(2014): Ludwig H+, Blood 123(7), 98538% (grade 3 or 4) (with bendamustine and bortezomib)
(2014): Richardson PG+, Blood 123(10), 146122% (grade 3 or 4) (with bortezomib and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 182619% (grade 3 or 4) (with pomalidomide)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 119531% (grade 3 or 4) (with bortezomib)
(2014): Zhang Y+, Pathol Oncol Res 20(4), 98713–38% (with bortezomib and doxorubicin)
(2013): Fouquet G+, Cancer 119(20), 36806% (grade 3–4) (with lenalidomide)
(2013): Lamm W+, J Cancer Res Clin Oncol 139(10), 177133% (grade 2+) (with cytarabine, oxaliplatin and rituximab)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 105526% (grade 3 or 4) (high-dose)
(2013): Richardson PG+, Blood 122(14), 233166% (with bortezomib and panobinostat)
(2013): San Miguel J+, Lancet Oncol 14(11), 105526% (grade 3 or 4) (high-dose)
(2013): San-Miguel JF+, J Clin Oncol 31(29), 369667–85% (grade 3 or 4) (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312231% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167535% (with bortezomib, doxorubicin and lenalidomide)
(2012): Jakubowiak AJ+, Blood 120(9), 180117% (low-dose / with carfilzomib and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47216% (with lenalidomide and perifosine)
(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)
(2012): Zaja F+, Haematologica 97(3), 41622% (with lenalidomide)
(2010): Richardson PG+, Blood 116(5), 6796% (with lenalidomide and bortezomib)
Thrombosis
(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2926% (deep vein) (with lenalidomide)
(2010): Richardson PG+, Blood 116(5), 6796% (with lenalidomide and bortezomib)
Infusion-related reactions
(2016): Mateos MV+, Br J Haematol 175(3), 44815% (with elotuzumab and thalidomide)
(2016): Palumbo A+, N Engl J Med 375(8), 75445% (with bortezomib and daratumumab)
Infusion-site reactions
(2016): Plesner T+, Blood 128(14), 182156% (with daratumumab and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 1953 (with elotuzumab and lenalidomide)
Injection-site reaction
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Arthralgia
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Wang M+, Blood 122(18), 312225% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)
(2003): Jain R+, J Dermatol 30(10), 71314% (with cyclophosphamide)
(1991): Weissman DE+, J Neurooncol 11(3), 235
Asthenia / fatigue
(2020): Palladini G+, Blood Apr, Epub ahead of print54% (with daratumumab, cyclophosphamide and bortezomib)
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2018): Hansen VL+, Clin Lymphoma Myeloma Leuk Mar, Epub ahead of print31% (grade 3 or 4) (with bortezomib and panobinostat)
(2018): Li CS+, Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(3), 836 (with bortezomib and thalidomide)
(2018): Mikhael J+, Blood Cancer J 8(9) (with lenalidomide)
(2018): Sonbol MB+, Leuk Lymphoma Jan, Epub ahead of print14% (grade 3+) (with bortezomib, cyclophosphamide and rituximab)
(2017): Berdeja JG+, Br J Haematol 177(2), 254 (with bendamustine and bortezomib)
(2016): Berenson JR+, Blood 127(26), 336011% (grade 3+) (with carfilzomib)
(2016): Mateos MV+, Lancet Oncol 17(8), 11276% (grade 3) (with lenalidomide)
(2016): Mateos MV+, Br J Haematol 175(3), 44835% (grade 3+) (with elotuzumab and thalidomide)
(2016): Richardson PG+, Expert Rev Clin Pharmacol 9(1), 35 [REVIEW]24% (grade 3 or 4) (with bortezomib and panobinostat)
(2016): Richardson PG+, Blood 127(6), 713 (grade 3 or 4) (with bortezomib and panobinostat)
(2015): Gupta N+, J Hematol Oncol 8, 10316% (with lenalidomide and ixazomib)
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Ocio EM+, Haematologica 100(7), e289 (with panobinostat)
(2015): Richardson PG+, Lancet Haematol 2(12), e51656% (with elotuzumab and dexamethasone)
(2015): Usmani SZ+, Blood Cancer J 5, e334100% (with bortezomib, elotuzumab and lenalidomide)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (3 cases) (with oxaliplatin)
(2014): Baz RC+, Am J Hematol 89(1), 6214% (grade 3 or 4) (with doxorubicin and lenalidomide)
(2014): Richardson PG+, Blood 123(10), 146150% (with bortezomib and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 182614% (grade 3 or 4) (with pomalidomide)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 119512% (grade 3 or 4) (with bortezomib)
(2014): Siegel DS+, Blood Cancer J 4, e18255% (with lenalidomide and vorinostat)
(2014): Takeshima N+, Support Care Cancer 22(11), 2891 (3 cases) (with aprepitant and palonosetron)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 10556% (grade 3 or 4) (high-dose)
(2013): Richardson PG+, Blood 122(14), 233120–69% (with bortezomib and panobinostat)
(2013): San Miguel J+, Lancet Oncol 14(11), 10556% (grade 3 or 4) (high-dose)
(2013): San-Miguel JF+, J Clin Oncol 31(29), 369620–30% (grade 3 or 4) (with bortezomib and panobinostat)
(2013): Wang M+, Blood 122(18), 312269% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167540% (with bortezomib, doxorubicin and lenalidomide)
(2012): Jakubowiak AJ+, Br J Haematol 158(4), 47248% (with lenalidomide and perifosine)
(2012): Kumar S+, Blood 119(19), 4375 (with bortezomib, cyclophosphamide and lenalidomide)
(2012): Kumar SK+, Blood 119(21), 4860 (with cyclophosphamide and lenalidomide)
(2012): Lentzsch S+, Blood 119(20), 4608 (with bendamustine and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195321–61% (with elotuzumab and lenalidomide)
(2011): Hus M+, Ann Hematol 90(10), 116119% (with thalidomide)
(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2915% (with lenalidomide)
(2010): Richardson PG+, Blood 116(5), 67964% (with lenalidomide and bortezomib)
(2005): Richardson PG+, N Engl J Med 352(24), 2487
(2003): Jain R+, J Dermatol 30(10), 71354% (with cyclophosphamide)
(1997): Borgna-Pignatti C+, J Pediatr 130(1), 13-6
(1993): Pasricha JS+, Int J Dermatol 32(10), 753
Back pain
(2017): Kumar S+, Br J Haematol 178(4), 571 (with ixazomib and lenalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 182610% (grade 3 or 4) (with pomalidomide)
(2013): Wang M+, Blood 122(18), 312231% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195325% (with elotuzumab and lenalidomide)
Bone or joint pain
(2013): Miguel JS+, Lancet Oncol 14(11), 10555% (grade 3 or 4) (high-dose)
(2013): San Miguel J+, Lancet Oncol 14(11), 10555% (grade 3 or 4) (high-dose)
(2005): Richardson PG+, N Engl J Med 352(24), 2487
(1994): Chan-Lam D+, Br J Haematol 86(1), 227
Muscle spasm
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2015): Richardson PG+, Lancet Haematol 2(12), e51662% (with elotuzumab and lenalidomide)
(2013): Wang M+, Blood 122(18), 312239% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195332% (with elotuzumab and lenalidomide)
Myalgia/Myositis/Myopathy/Myotoxicity (see also statin-induced necrotizing autoimmune myopathy)
(2014): Richardson PG+, Blood 123(12), 18264% (grade 3 or 4) (with pomalidomide)
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2005): Richardson PG+, N Engl J Med 352(24), 2487
(2001): Hardy JR+, Palliat Med 15(1), 3-8
(1995): Koehler PJ, Anticancer Drugs 6(1), 19-3 [REVIEW]
(1991): Dropcho EJ+, Neurology 41(8), 1235
Osteonecrosis / avascular necrosis
(2021): M Lewis-Gonzalez J+, CNS Oncol Oct, Online ahead of print (1 case / female)
(2014): Mondello P+, Springerplus 3, 123 [REVIEW] (with ibandronate and lenalidomide)
(2005): Burger B+, Pediatr Blood Cancer 44(3), 220
(2004): van den Berkmortel F+, Neth J Med 62(1), 23-7
(2001): Strauss AJ+, J Clin Oncol 19(12), 3066
(2001): van Schaardenburg D+, Ned Tijdschr Geneeskd 145(37), 1769 [REVIEW]
(2001): Virik K+, Int J Clin Pract 55(5), 344
(2000): Mattano LA Jr+, J Clin Oncol 18(18), 3262
(1999): Ojala AE+, Med Pediatr Oncol 32(1), 11-7
(1997): Ojala AE+, Med Pediatr Oncol 29(4), 260
(1997): Thornton MJ+, Clin Radiol 52(8), 607
(1994): Osebold WR+, Iowa Orthop J 14, 120
(1990): Murphy RG+, Cancer 65(8), 1717
(1984): Fast A+, J Neurosurg 61(5), 983
(1982): McCluskey J+, Br Med J (Clin Res Ed) 284(6312), 333
(1981): Black KA+, Aust N Z J Med 11(5), 521
Osteoporosis
(2018): Zhang L+, J Pharm Sci Nov, Epub ahead of print (passim)
(2004): Raff H, Trends Endocrinol Metab 15(8), 351
(1999): Fuchs M+, HNO 47(7), 647
(1988): Kruse K+, Monatsschr Kinderheilkd 136(5), 237
Cataract <10%
(2018): Blanc J+, Graefes Arch Clin Exp Ophthalmol May, Epub ahead of print70%
(2018): Tufail A+, Clin Ophthalmol 12, 2519 [REVIEW]
(2018): Yoon YH+, Ophthalmologica Apr, Epub ahead of print16% (newly diagnosed)
(2017): Fassbender Adeniran JM+, Ocul Immunol Inflamm 25(6), 834 [REVIEW]
(2016): Korobelnik JF+, Graefes Arch Clin Exp Ophthalmol 254(12), 230740% (progression)
(2014): Lambiase A+, Drugs Today (Barc) 50(3), 239
(2003): Jain R+, J Dermatol 30(10), 713 (with cyclophosphamide)
(1994): Zheng Y+, Yan Ke Xue Bao 10(2), 102
(1989): Mohan R+, Indian J Ophthalmol 37(1), 13-6
(1986): Bluming AZ+, J Clin Oncol 4(2), 221
Conjunctivitis
(1995): Valdivieso R+, J Investig Allergol Clin Immunol 5(3), 171 (1 case) (with paramethasone)
Glaucoma
(2014): Lambiase A+, Drugs Today (Barc) 50(3), 239
(2012): Mataftsi A+, J Cataract Refract Surg 38(10), 1719
(2006): Mentink LF+, Arch Dermatol 142(5), 570
(2003): Jain R+, J Dermatol 30(10), 713 (3 cases) (with cyclophosphamide)
(1999): Tan DT+, Ophthalmology 106(2), 223
(1995): Kong L+, Yan Ke Xue Bao 11(1), 53-6
(1993): Aggarwal RK+, Eye 7, 664
(1993): Kong LX, Zhonghua Yan Ke Za Zhi 29(3), 151
(1989): Mohan R+, Indian J Ophthalmol 37(1), 13-6
Intraocular pressure increased >10%
(2018): Blanc J+, Graefes Arch Clin Exp Ophthalmol May, Epub ahead of print55%
(2018): Li X+, Graefes Arch Clin Exp Ophthalmol 256(1), 59
(2018): Tufail A+, Clin Ophthalmol 12, 2519 [REVIEW]19%
(2018): Yoon YH+, Ophthalmologica Apr, Epub ahead of print35%
(2017): Eter N+, Graefes Arch Clin Exp Ophthalmol 255(1), 77
(2017): Malcles A+, Retina 37(4), 75310% (transient)
(2017): Malcles A+, Retina 37(7), 135229%
(2016): Korobelnik JF+, Graefes Arch Clin Exp Ophthalmol 254(12), 230734%
(2016): Matonti F+, Eur J Ophthalmol 26(5), 45413%
(2016): Novais EA+, J Ophthalmol Sep, Epub23%
(2015): Sheu SJ+, J Ocul Pharmacol Ther 31(8), 46111%
(2014): Ford JA+, BMJ Open 4(2), e004120 [REVIEW]
(2012): Chen M+, Curr Med Res Opin 28(3), 385 (with tobramycin)
(2008): White EM+, Curr Med Res Opin 24(1), 287
Ocular adverse effect
(2021): Contreras-Salinas H+, Pharmacy (Basel) 9(1), E15 (with ciprofloxacin)
(2016): Hoerauf H+, Am J Ophthalmol 169, 25887%
Ocular hypertension <10%
(2021): Tasaki A, Optom Vis Sci 98(8), 867-869 (1 case / male) (with chemotherapy)
(2017): Fassbender Adeniran JM+, Ocul Immunol Inflamm 25(6), 834
(2015): Pelegrin L+, Eye (Lond) 29(7), 94348%
(2013): Kiddee W+, Surv Ophthalmol 58(4), 291 [REVIEW]11–15%
(2001): Dinning WJ+, Ophthalmology 108(10), 1715
(2000): Ng JS+, Ophthalmology 107(11), 2097
(1999): Deng Y+, Hua Xi Yi Ke Da Xue Xue Bao 30(2), 205
Ocular pain <10%
(2014): Dang Y+, Drug Des Devel Ther 8, 1441 (mild)
(1999): Deng Y+, Hua Xi Yi Ke Da Xue Xue Bao 30(2), 205
(1997): Kwok AK+, Ophthalmology 104(12), 2112
(1995): Clark AF+, Invest Ophthalmol Vis Sci 36(2), 478
(1986): Kass M+, Am J Ophthalmol 102(2), 159
(1984): Stewart RH+, Curr Eye Res 3(6), 835
Vision blurred
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Demirhan A+, Aesthetic Plast Surg 37(6), 1100 (with pregabalin)
(2003): Jain R+, J Dermatol 30(10), 7139% (with cyclophosphamide)
Ototoxicity
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(1998): Abello P+, Acta Otorrinolaringol Esp 49(5), 353
(1998): Arditi M+, Pediatrics 102(5), 1087
(1994): Syrogiannopoulos GA+, J Infect Dis 169(4), 853
Tinnitus
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
(2017): Boccia RV+, Clin Lymphoma Myeloma Leuk 17(7), 43313% (grade 3+) (with carfilzomib and cyclophosphamide)
(2016): Ping LY+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(9), 790 (1 case) (with cisplatin, etoposide and ifosfamide)
Renal failure
(2018): Siegel DS+, J Clin Oncol Jan, Epub ahead of print3% (grade 3+) (with dexamethasone)
(2014): Richardson PG+, Blood 123(12), 18265% (grade 3 or 4) (with pomalidomide)
Tumor lysis syndrome (TLS)
(2017): Khan F+, Oxf Med Case Reports 2017(5)
(2008): McDonnell C+, Anaesthesia 63(6), 652 (fatal)
(2008): Osthaus WA+, Paediatr Anaesth 18(3), 268
Cough
(2018): Comeau JM+, Am J Health Syst Pharm 75(2), 55 [REVIEW] (with elotuzumab and lenalidomide)
(2014): Siegel DS+, Blood Cancer J 4, e18245% (with lenalidomide and vorinostat)
(2013): Wang M+, Blood 122(18), 312240% (with carfilzomib and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195321% (with elotuzumab and lenalidomide)
Dyspnea / shortness of breath
(2015): Niesvizky R+, Leuk Lymphoma 56(12), 3320 (with bortezomib and palbociclib)
(2015): Shah JJ+, Blood 126(20), 2284 (with carfilzomib and pomalidomide)
(2015): Usmani SZ+, Blood Cancer J 5, e33433% (with bortezomib, elotuzumab and lenalidomide)
(2014): Richardson PG+, Blood 123(12), 182613% (grade 3 or 4) (with pomalidomide)
(2013): Wang M+, Blood 122(18), 312237% (with carfilzomib and lenalidomide)
Flu-like syndrome
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
Pleural effusion
(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)
Pneumonia
(2017): Badros A+, Blood 130(10), 118915% (grade 3 or 4) (with pembrolizumab and pomalidomide)
(2017): Kwon J+, Cancer Med 6(1), 100 (fatal / 1 case) (with cyclophosphamide and thalidomide)
(2016): Dimopoulos MA+, Lancet Oncol 17(1), 277–8% (grade 3+) (with bortezomib or carfilzomib)
(2016): Shah JJ+, Blood Cancer J 6, e396 (grade 3) (with bortezomib, lenalidomide and siltuximab)
(2015): Yoshida Y+, Drug Des Devel Ther 9, 6067 (1 case) (with oxaliplatin)
(2014): Keino D+, Rinsho Ketsueki (Japanese) 55(3), 327 (with bortezomib, doxorubicin and vincristine)
(2014): Richardson PG+, Blood 123(12), 182622% (grade 3 or 4) (with pomalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 10558% (grade 3 or 4) (high-dose)
(2013): Richardson PG+, Blood 122(14), 233116% (with bortezomib and panobinostat)
(2013): San Miguel J+, Lancet Oncol 14(11), 10558% (grade 3 or 4) (high-dose)
(2013): Wang M+, Blood 122(18), 312217% (with carfilzomib and lenalidomide)
(2012): Berenson JR+, Leukemia 26(7), 167515% (with bortezomib, doxorubicin and lenalidomide)
(2012): Lonial S+, J Clin Oncol 30(16), 195314% (with elotuzumab and lenalidomide)
(2010): Rajkumar SV+, Lancet Oncol 11 (1), 2916% (with lenalidomide)
Pneumonitis
(2017): Badros A+, Blood 130(10), 118913% (with pembrolizumab and pomalidomide)
(2013): Hatano K+, Int J Clin Oncol 18(4), 704 (grade 3+ / 4 cases) (with docetaxel and estramustine)
Pulmonary toxicity
(2012): Lonial S+, J Clin Oncol 30(16), 19537% (with elotuzumab and lenalidomide)
Upper respiratory tract infection
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (fatal / 1 case) (with lenalidomide)
(2013): Wang M+, Blood 122(18), 312244% (with carfilzomib and lenalidomide)
Adverse effects
(2021): Toroghi N+, Pharmacol Rep Nov, Online ahead of print (with concomitant medication)
(2018): Soyer N+, Turk J Med Sci 48(4), 77758% (with lenalidomide)
(2017): Patel P+, Br J Clin Pharmacol 83(10), 2148 [REVIEW] (pharmacokinetic interaction with aprepitant or fosaprepitant)
(2016): Berdeja J+, Clin Lymphoma Myeloma Leuk 16(3), 129 (with elotuzumab and lenalidomide)
(2016): Liu HB+, Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese) 24(2), 498 (4 cases) (gastrointestinal / with lenalidomide)
(2016): Prud'homme M+, Can J Neurol Sci 43(2), 284
(2015): Cibeira MT+, Br J Haematol 170(6), 80414% (with cyclophosphamide and lenalidomide)
(2015): Sharma A+, Perspect Clin Res 6(2), 109<1%
(2015): Stewart AK+, N Engl J Med 372(2), 14281% (grade 3+) (with lenalidomide)
(2014): Bringhen S+, Blood 124(1), 637% (grade 3+) (cardiopulmonary / with carfilzomib and cyclophosphamide)
(2014): Lazaryan A+, Am J Hematol 89(4), 349 (with doxorubicin, lenalidomide and vincristine)
(2014): Leiba M+, Br J Haematol 166(5), 702 [REVIEW]74% (grade 3 or 4) (with bortezomib and cyclophosphamide)
(2014): San-Miguel JF+, Lancet Oncol 15(11), 119542% (serious) (with bortezomib)
(2012): Kumar SK+, Blood 119(21), 4860 (gastrointestinal / with cyclophosphamide and lenalidomide)
(2005): Richardson PG+, N Engl J Med 352(24), 248760%
(2004): Borst F+, Ann Hematol 83(12), 764
(2004): May C+, Monaldi Arch Chest Dis 61(3), 162 [REVIEW]
(2004): Odd DE+, J Paediatr Child Health 40(5-6), 282
(2004): Palladini G+, Blood 103(8), 293611% (with melphalan)
(1998): Yeh TF+, Pediatrics 101(5), E7
(1986): Garden JM+, Arch Dermatol 122(9), 1007
Allergic reactions
(2011): Hus M+, Ann Hematol 90(10), 11615% (with thalidomide)
(1989): Brambilla L+, Contact Dermatitis 21(4), 272
Death
(2017): Kwon J+, Cancer Med 6(1), 100 (3 cases) (with cyclophosphamide and thalidomide)
(2014): Lazaryan A+, Am J Hematol 89(4), 349 (4 cases) (with doxorubicin, lenalidomide and vincristine)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (1 case) (with lenalidomide)
(2013): Miguel JS+, Lancet Oncol 14(11), 10555% (high-dose)
(2013): San Miguel J+, Lancet Oncol 14(11), 10555% (high-dose)
(2008): McDonnell C+, Anaesthesia 63(6), 652
(1994): Malik IA+, South Med J 87(3), 409
(1992): Heimdal K+, J Neurooncol 12(2), 141
(1992): O'Neil EA+, Arch Dis Child 67(1), 10-1
(1991): Friedenberg WR+, Am J Hematol 36(3), 171
(1990): Ferrara TB+, J Perinatol 10(2), 137
Hiccups
(2018): Kim J+, Eur J Oncol Nurs 37, 23
(2017): Go SI+, Oncologist 22(11), 1354
(2017): Ioroi T+, Support Care Cancer Nov, Epub ahead of print48% (with aprepitant and palonosetron)
(2016): de Arriba Mendez JJ, Med Clin (Barc) (Spanish) 146(6), 284
(2016): Yang CK+, Biomed J 39(1), 6026% (with aprepitant and palonosetron)
(2015): El Abd O+, Pain Physician 18(3), 277
(2014): Hamada S+, Support Care Cancer 22(8), 216113% (with aprepitant and palonosetron)
(2012): Kang JH+, J Pain Symptom Manage 43(3), 625 (5 cases)
(2009): Gilbar P+, J Oncol Pharm Pract 15 (4), 233
(2005): Errante D+, Gut 54(10), 1503
(2005): Liaw CC+, J Pain Symptom Manage 30(4), 359
(2003): Jain R+, J Dermatol 30(10), 713 (9 cases) (with cyclophosphamide)
(2001): Eguchi F+, Gan To Kagaku Ryoho 28(10), 1423 (with ondansetron)
(2001): Horichi N+, Gan To Kagaku Ryoho 28(7), 953
(1999): Ross J+, West J Med 170(1), 51-2
(1998): Cersosimo RJ+, Cancer 82(2), 412
(1996): Sekine I+, Jpn J Clin Oncol 26(3), 164
(1993): Jaime Vazquez J, Hum Exp Toxicol 12(1), 52
(1982): LeWitt PA+, Ann Neurol 12(4), 405
Infection
(2019): Tanaka K+, Acta Haematol 141(2), 1114 cases (grade 3–4) (with cyclophosphamide and bortezomib)
(2017): Lu J+, Br J Haematol 176(5), 74319% (grade 3 or 4) (with lenalidomide)
(2017): Moreau P+, Eur J Haematol 99(3), 19934% (grade 3 or 4) (with pomalidomide)
(2017): Palladini G+, Blood 129(15), 2120 (with pomalidomide)
(2017): Paludo J+, Br J Haematol 179(1), 983% (grade 3+) (with cyclophosphamide and rituximab)
(2016): Mateos MV+, Lancet Oncol 17(8), 11276% (grade 3) (with lenalidomide)
(2015): Ding H+, Int J Hematol 102(2), 18115% (with etoposide, methotrexate and pegaspargase)
(2015): Kim HJ+, Blood Res 50(1), 7 [REVIEW] (with lenalidomide)
(2015): Rodon P+, Haematologica 100(2), e56 (with bendamustine and bortezomib)
(2015): Usmani SZ+, Blood Cancer J 5, e33416% (with bortezomib, elotuzumab and lenalidomide)
(2014): Benjamini O+, Am J Hematol 89(3), 282 (grade 3 or 4) (in hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus dasatinib)
(2014): Ludwig H+, Blood 123(7), 98523% (grades 3 to 5) (with bendamustine and bortezomib)
(2013): Mateos MV+, N Engl J Med 369(5), 438 (with lenalidomide)
(2013): Voorhees PM+, Br J Haematol 161(3), 35757% (with siltuximab)
(2012): Zaja F+, Haematologica 97(3), 41612% (with lenalidomide)
(2004): Mantadakis E+, Pediatr Hematol Oncol 21(1), 27-3
(2003): Belgaumi AF+, Cancer 97(11), 289836%
(1999): Stoll BJ+, Pediatrics 104(5), e63
(1998): Hari P+, Indian J Pediatr 65(4), 557 [REVIEW]
(1998): Papile LA+, N Engl J Med 338(16), 1112
(1998): Thomas MC+, Int J Clin Pract 52(7), 520
(1995): Koehler PJ, Anticancer Drugs 6(1), 19-3 [REVIEW]
(1994): Keogh P+, Neurosurgery 34(2), 364
(1994): Sharada B+, Rheumatol Int 14(3), 91-4
(1991): Friedenberg WR+, Am J Hematol 36(3), 171
(1990): Ferrara TB+, J Perinatol 10(2), 137
(1990): Karnik R+, Wien Klin Wochenschr 102(1), 1-4
(1990): Ng PC+, Arch Dis Child 65(1 Spec No), 54-6
(1985): Moskopp D, Neurochirurgia (Stuttg) 28(3), 147
(1983): Hanks GW+, Postgrad Med J 59(697), 702
(1980): West BC+, Am J Ophthalmol 89(6), 854
Side effects
(2001): Hamon I+, J Gynecol Obstet Biol Reprod (Paris) 30(6), S50 [REVIEW]
(1997): Kuhne T+, J Pediatr 130(1), 17-2
(1996): Ralls JE, Aust Fam Physician 25(5), 713
Adverse reactions attributed to entire drug class Antiemetic
Akathisia
(2018): Rashid A+, Psychooncology 27(4), 1338 [REVIEW]5%
Adverse effects
(2021): Eliasen A+, Pharmacogenet Genomics Nov, Online ahead of print
Adverse reactions attributed to entire drug class Corticosteroid / Glucocorticoid
Atrophy / Skin atrophy
(2020): Niculet E+, Clin Cosmet Investig Dermatol 13, 1041-1050 [REVIEW]
Cushingoid features
(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Cutaneous adverse reaction / severe cutaneous adverse drug reaction (SCAR)
(2013): Guillot B, Rev Med Interne (French) 34(5), 310-4 [REVIEW]
Hirsutism
(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Behavioral disturbances / personality changes
(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Cognitive impairment
(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Depression
(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
(2011): Celano CM+, Dialogues Clin Neurosci 13(1), 109 [REVIEW]
Insomnia
(2017): Ismail MF+, Future Oncol [REVIEW]
Mania
(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Mood changes
(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Neuropsychiatric / neuropsychological adverse effect
(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
Neurotoxicity
(2014): Prescrire Int 23(150), 153 (violent behavior)
Psychiatric adverse effect
(2019): Staub Y+, J Oncol Pharm Pract Oct, Epub ahead of print65–78%
Psychosis
(2021): Huynh G+, J Pharm Technol 37(2), 120-126 [REVIEW] (13 cases)
(2017): Ismail MF+, Future Oncol 13(29), 2719 [REVIEW]
Sleep disturbances
(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
Diabetes mellitus
(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
Hyperglycemia (includes glucose increased)
(2020): Delfs N+, J Clin Med 9(12), E407934%
Hypoglycemia
(2020): Delfs N+, J Clin Med 9(12), E40794%
Weight gain
(2016): Matthews E+, Cochrane Database Syst Rev (5), CD003725 [REVIEW]
Gastrointestinal disorder / discomfort
(2019): Qian G+, Int Urol Nephrol March, Epub ahead of print [REVIEW]
Pancreatitis / acute pancreatitis
(2010): Lipsker D+, Dermatology 220 (3), 264
(2010): Ouakaa-Kchaou A+, Tunis Med 88 (2)
(2008): Bhavsar B+, JOP 9 (5), 664
(2008): Cagdas DN+, J Cardiovasc Pharmacol Ther 13 (4), 298
(2008): Tsuruoka K+, Nihon Jinzo Gakkai Shi 50 (7), 948
(2007): Fardet L+, Drug Saf 30 (10), 861
(2005): Trivedi CD+, J Clin Gastroenterol 39 (8), 709
(2003): Boruchowicz A+, Gastroenterol Clin Biol 27 (5), 560
Osteonecrosis / avascular necrosis
(2021): Zgheib NK+, Per Med Aug, Online ahead of print7% (grade 4)
Osteoporosis
(2021): Cho SK+, Endocrinol Metab (Seoul) Jun, Online ahead of print [REVIEW]
(2020): Ward LM, Front Endocrinol (Lausanne) Dec, eCollection
Tendinopathy/Tendon rupture
(2016): Knobloch K, Adv Exp Med Biol 920, 229
Cataract
(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
(2010): Habot-Wilner Z+, Acta Ophthalmol 88 (8), e299
(2010): Lee SW+, Acta Ophthalmol 88 (8), e344
(2010): Taylor JB+, J Child Neurol 25 (8), 1017
(2010): Thorne JE+, Ophthalmology 117 (7), 1436
(2009): Weatherall M+, Respirology 14 (7), 983
(2008): Nerome Y+, Pediatr Int 50 (4), 541
(2007): James ER, J Ocul Pharmacol Ther 23 (5), 403
(2006): Conti SM+, Curr Opin Ophthalmol 17 (3), 235
(2006): Ernst P+, Eur Respir J 27 (6), 1168
(2006): Gartlehner G+, Ann Fam Med 4 (3), 253
Chorioretinopathy
(2006): Bouyon A+, Rev Med Interne 27 (6), 487
Endophthalmitis
(2006): Conti SM+, Curr Opin Ophthalmol 17 (3), 235
Glaucoma
(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
(2010): Lee SW+, Acta Ophthalmol 88 (8), e344
(2007): El Afrit MA+, J Fr Ophtalmol 30 (1), 49
Pneumonia
(2016): Broder MS+, Semin Arthritis Rheum 46(2), 246 [REVIEW]
Adverse effects
(2021): Ma S+, Signal Transduct Target Ther 6(1), 83 [REVIEW] (passim)
(2021): Santiago T+, Rheumatology (Oxford) Jan, Online ahead of print [REVIEW]
(2020): Cheng W+, Front Pharmacol Sep, eCollection [REVIEW] (mild) (passim)
(2020): Sterne JAC+, JAMA Sep, Online ahead of print [REVIEW]
Adverse reactions attributed to entire drug class Corticosteroid, systemic
Bradycardia / sinus bradycardia
(2019): Duffy C+, J Pediatr Hematol Oncol Apr, Epub ahead of print98% (with induction chemotherapy)
Mania
(2021): Chen P+, Cureus 13(1), e12594 (1 case / female)
Neuropsychiatric / neuropsychological adverse effect
(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
Sleep disturbances
(2020): Cole JL, Fed Pract 37(6), 260-267 [REVIEW]
Diabetes mellitus
(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub
Asthenia / fatigue
(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub
Osteoporosis
(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub
Cataract
(2015): Satyanarayanasetty D+, J Clin Diagn Res 9(5), Epub
Adverse effects
(2017): Aljebab F+, PLoS One 12(1), Epub [REVIEW]
Adverse reactions attributed to entire drug class Corticosteroid, topical
Acneiform eruption / acneiform dermatitis / acneiform rash
(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Atrophy / Skin atrophy
(2019): Ah YM+, Basic Clin Pharmacol Toxicol Apr, Epub ahead of print
(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]
(2015): Barnes L+, Drug Saf 38(5), 493 [REVIEW]
Burning / skin burning sensation
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Cutaneous adverse reaction / severe cutaneous adverse drug reaction (SCAR)
(2017): Sharma R+, J Dermatol Case Rep 11(1), 5-8 (facial dermatoses)
Erythema
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Pigmentation
(2019): Ah YM+, Basic Clin Pharmacol Toxicol Apr, Epub ahead of print
(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Pruritus (itching)
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Striae
(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]
(2016): Nagesh TS+, Indian J Dermatol 61(6), 618
Telangiectasia
(2018): Shukla S+, Expert Opin Drug Saf 17(2), 179 [REVIEW]
Leukoplakia
(2015): Vigarios E+, Ann Dermatol Venereol (French) 142(10), 572
Adverse effects
(2016): Mehta AB+, Indian J Dermatol Venereol Leprol 82(4), 371 [REVIEW]
Adverse reactions attributed to entire drug class Covid-19 putative drug
Cutaneous adverse reaction / severe cutaneous adverse drug reaction (SCAR)
(2020): Tursen U+, Dermatol Ther May, Epub ahead of print [REVIEW]
Cardiovascular adverse effect
(2020): Carpenter A+, Front Cardiovasc Med 7, 85 [REVIEW]
(2020): Giudicessi JR+, Mayo Clin Proc May, Online ahead of print [REVIEW]
(2020): Naksuk N+, Eur Heart J Acute Cardiovasc Care May, Epub ahead of print [REVIEW]
(2020): Sarayani A+, Res Social Adm Pharm Apr, Epub ahead of print [REVIEW]
(2020): Zhang D+, Zhongguo Zhong Yao Za Zhi (Chinese) 45(10), 2275-2286 [REVIEW]
Neuropsychiatric / neuropsychological adverse effect
(2021): Borah P+, Front Mol Biosci 8, 627723
(2020): García CAC+, Gen Hosp Psychiatry Jun, Online ahead of print [REVIEW]
Gastrointestinal disorder / discomfort
(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print23%
Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction
(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print14%
Thrombocytopenia
(2020): Nham E+, Infect Chemother Apr, Epub ahead of print
Adverse effects
(2021): Bérard A+, PLoS One 16(5), e0251746 [REVIEW] (in pregnancy)
(2021): Cheng Q+, Aging (Albany NY) Sep, Online ahead of print [REVIEW]
(2021): Cruciani F+, Recenti Prog Med 112(3), 195-206 [REVIEW]
(2021): Ommati MM+, J Biochem Mol Toxicol May, Online ahead of print [REVIEW]
(2021): Qiu R+, Medicine (Baltimore) 100(16), e25532 [REVIEW]
(2021): Wu SS+, Chin Med J (Engl) Jul, Online ahead of print [REVIEW]
(2020): Favilli A+, J Matern Fetal Neonatal Med Jun, Online ahead of print [REVIEW]
(2020): Griffiths G+, Trials 21(1), 544
(2020): Patil VM+, Life Sci May, Epub ahead of print [REVIEW]
(2020): Rhodes NJ+, medRxiv Jun, Preprint
(2020): Sun J+, Clin Pharmacol Ther Apr, Epub ahead of print38%
(2020): Svensson M, Lakartidningen (Swedish) Apr, 117
(2020): Wen CY+, Zhonghua Nei Ke Za Zhi (Chinese) May, Epub ahead of print
(2020): Zekarias A+, Drug Saf Sep, Online ahead of print [REVIEW]
(2020): Zhong H+, Pharmacol Res Apr, Epub ahead of print [REVIEW]
Page last updated 11/30/2021
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
